Alvotech
ALVOW- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001898416
No open-market purchases or sales by Alvotech insiders were filed in the last 90 days; 7 institutions reported holding it in 13F filings for Q2 2026, worth $1.16M in total; Oaktree Capital is the only superinvestor holding it.
Other share classesALVO
Q3 2025 vs. Q2 2025
How the institutions holding Alvotech changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Of which not filed for Q3 2025 | Q3 2025 | Change |
|---|---|---|---|---|
| Holders | 11 | 1 | 10 | 0 |
| Shares | 5.16M | 5.83K | 5.10M | −53.9K (−1.0%) |
| Value | $9.09M | $9.91K | $7.74M | −$1.34M (−14.8%) |
1 institution that held it in Q2 2025 haven't filed for Q3 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (2)
Institutions that held Alvotech at the end of Q3 2025 but not at the end of Q2 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Highbridge Capital Management LLC | – | $8.88K | 0.00% |
| Clear Street Group Inc. | 5,828 | $8.85K | 0.00% |
Sold out (2)
Institutions that held Alvotech at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Bluefin Capital Management, LLC | 12,608 | $16.8K |
| Royal Bank of Canada | 1,397 | $2.00K |
Not filed for Q3 2025 yet (1)
Institutions that held Alvotech at the end of Q2 2025 and haven't filed a 13F for Q3 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Clear Street LLC | 5,828 | $9.91K |